Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Nls Pharmaceutics Ltd (NLSP)

Nls Pharmaceutics Ltd (NLSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute PR Newswire - Mon Nov 17, 6:00AM CST

ZURICH and NESS ZIONA, Israel , Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd . (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule...

NCEL : 2.91 (-12.61%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger PR Newswire - Thu Oct 30, 3:15PM CDT

Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL"

NLSPW : 0.0179 (-3.24%)
NLS : 0.8204 (+11.20%)
NCEL : 2.91 (-12.61%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs PR Newswire - Thu Oct 30, 6:00AM CDT

ZURICH , Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger PR Newswire - Wed Oct 29, 6:00AM CDT

ZURICH , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous...

NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem PR Newswire - Wed Oct 29, 5:00AM CDT

ZURICH , Oct. 29, 2025 /PRNewswire/ --  NLS Pharmaceutics Ltd.  (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares PR Newswire - Wed Oct 29, 2:53AM CDT

ZURICH and NESS ZIONA, Israel , Oct. 29, 2025 /PRNewswire/ --  NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and  Kadimastem Ltd. (TASE: KDST) ("Kadimastem")...

NLSPW : 0.0179 (-3.24%)
KMSTF : 5.0600 (-0.78%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies PR Newswire - Mon Oct 27, 6:00AM CDT

The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 PR Newswire - Thu Oct 23, 5:01AM CDT

ZURICH , Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.  (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Announces Strategic Merger with Kadimastem Tipranks - Sat Oct 11, 5:38AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. NLS Pharmaceutics...

NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting PR Newswire - Tue Sep 30, 6:00AM CDT

Vote clears final corporate milestone, paving the way for the closing of the merger and the combined company of NewCelX Ltd., a Nasdaq-listed biotechnology company

NLSP : 7.6200 (+2.97%)

Barchart Exclusives

Inflation Data, AI Earnings and Other Can't Miss Items this Week Barchart - Sun Dec 14, 12:00PM CST
Markets enter a critical week still reeling from Friday's sharp selloff in technology and AI stocks following disappointing reactions to Oracle and Broadcom earnings that raised questions about AI infrastructure spending sustainability and return on massive capital investments. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot